Literature DB >> 30217491

Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer.

Thomas Yang Sun1, Xiaomin Niu2, Amit Chakraborty3, Joel W Neal1, Heather A Wakelee4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30217491     DOI： 10.1016/j.jtho.2018.08.2030

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  8 in total

1.  Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date.

Authors:  Francesco Facchinetti; Luc Friboulet
Journal:  Lung Cancer (Auckl)       Date:  2019-09-09

2.  Cabozantinib Is Effective in Melanoma Brain Metastasis Cell Lines and Affects Key Signaling Pathways.

Authors:  Trond Are Mannsåker; Tuyen Hoang; Synnøve Nymark Aasen; Ole Vidhammer Bjørnstad; Himalaya Parajuli; Terje Sundstrøm; Frits Alan Thorsen
Journal:  Int J Mol Sci       Date:  2021-11-14       Impact factor: 5.923

Review 3.  ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.

Authors:  Sébastien Gendarme; Olivier Bylicki; Christos Chouaid; Florian Guisier
Journal:  Curr Oncol       Date:  2022-01-28       Impact factor: 3.677

Review 4.  Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

Authors:  Vinayak Palve; Yi Liao; Lily L Remsing Rix; Uwe Rix
Journal:  Semin Cancer Biol       Date:  2020-02-07       Impact factor: 15.707

Review 5.  ROS1-dependent cancers - biology, diagnostics and therapeutics.

Authors:  Alexander Drilon; Chelsea Jenkins; Sudarshan Iyer; Adam Schoenfeld; Clare Keddy; Monika A Davare
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

Review 6.  ROS1 Targeted Therapies: Current Status.

Authors:  Christine M Azelby; Mandy R Sakamoto; Daniel W Bowles
Journal:  Curr Oncol Rep       Date:  2021-06-14       Impact factor: 5.075

Review 7.  Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.

Authors:  Alberto D'Angelo; Navid Sobhani; Robert Chapman; Stefan Bagby; Carlotta Bortoletti; Mirko Traversini; Katia Ferrari; Luca Voltolini; Jacob Darlow; Giandomenico Roviello
Journal:  Cancers (Basel)       Date:  2020-11-06       Impact factor: 6.639

8.  Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform.

Authors:  Clara Mayo de Las Casas; Mónica Garzón-Ibañez; Núria Jordana-Ariza; Santiago Viteri-Ramírez; Irene Moya-Horno; Niki Karachaliou; Zaira Yeste; Raquel Campos; Sergi Villatoro; Ariadna Balada-Bel; Beatriz García-Peláez; Noemí Reguart; Cristina Teixidó; Eloisa Jantús; Silvia Calabuig; Cristina Aguado; Ana Giménez-Capitán; Ruth Román-Lladó; Ana Pérez-Rosado; Maria José Catalán; Jordi Bertrán-Alamillo; Silvia García-Román; Sonia Rodriguez; Lidia Alonso; Erika Aldeguer; Alejandro Martínez-Bueno; Maria González-Cao; Andrés Aguilar Hernandez; Juan Garcia-Mosquera; Maria de Los Llanos Gil; Manuel Fernandez; Rafael Rosell; Miguel Ángel Molina-Vila
Journal:  Transl Cancer Res       Date:  2019-01       Impact factor: 1.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.